

RHEUMATOID ARTHRITIS AS AN AUTOIMMUNE DISORDER AND ITS AYURVEDIC CORRELATE AMAVATA

Dr. Durga Gorakh Satav^{*1}, Dr. Sandeep Gorakh Mane², Dr. Kaustubh Chandrashekhar Vaidya³, Dr. Bhupendra Prakash Khairnar⁴, Dr. Ganesh Tukaram Aher⁵

^{*1}BAMS, MD, PhD (Scholar) Department of Kayachikitsa, College of Ayurved, Bharati Vidyapeeth (Deemed to be university), Pune, Maharashtra, India. drdurgasatav28@gmail.com

²B.A.M.S, M.D (Phd Scholar) Profesor, Kayachikitsa Department, Pravara Rural Ayurved College and Hospital Loni, Ahilyanagar, Maharashtra, India. drsgmane@gmail.com

³BAMS, MD, Department of Kayachikitsa, Medical Officer, Seth Tarachand Hospital, Rastha Peth, Pune, Maharashtra, India. dr.kaustubhvaidya@gmail.com

⁴BAMS, MD, Associate Professor, Rasashastra and Bhaishajya Kalpana Department, Siddhakala Ayurved Mahavidyalay, Sangamner, Ahilyanagar, Maharashtra, India. dr.bhupendra.p.k@gmail.com

⁵BAMS, MD, Principal, Professor, Panchkarma Department, PMT Ayurved College and Hospital Loni, Ahilyanagar, Maharashtra, India.

Corrospoding Author

Dr. Durga Gorakh Satav

BAMS, MD, PhD (Scholar) Department of Kayachikitsa, College of Ayurved, Bharati Vidyapeeth (Deemed to be university), Pune, Maharashtra, India. drdurgasatav28@gmail.com

DOI: [https://doi.org/10.63001/tbs.2026.v21.i04.S.I\(4\).pp366-385](https://doi.org/10.63001/tbs.2026.v21.i04.S.I(4).pp366-385)

KEYWORDS

*Rheumatoid Arthritis;
Autoimmune Disease;
Amavata; Ayurveda;
Ayurvedic Management;
Inflammation; Joint Pain;
Sandhivata;
Immunomodulation;
Rasayana*

Received: 17/09 /2026

Accepted :04/10/2026

Published: 14/10/2026

Abstract

Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease characterized by persistent synovitis, autoantibody formation, progressive cartilage and bone damage, functional limitation, and extra-articular morbidity. Contemporary burden estimates indicate that approximately 17.6 million people were living with RA worldwide in 2020, with a marked female predominance and a projected rise in absolute case numbers as populations grow and age. The condition is driven by interactions among genetic susceptibility, environmental and mucosal exposures, loss of immune tolerance, adaptive and innate immune activation, and cytokine-mediated synovial pathology. Early diagnosis and prompt initiation of disease-modifying antirheumatic drugs (DMARDs) remain central to preventing irreversible structural damage. (Black et al., 2023)

Ayurvedic literature describes Amavata as a disorder arising from the interaction of Ama with aggravated Vata in the setting of impaired Agni, followed by systemic circulation, obstruction of channels, and localization in joints. Its clinical description shares several features with inflammatory polyarthritis, including joint pain, swelling, stiffness, heaviness, constitutional symptoms, and restricted movement. However, Amavata and biomedical RA are conceptual entities derived from different knowledge systems and should not be treated as perfectly interchangeable diagnoses. The present article therefore uses an integrative comparative approach rather than claiming one-to-one equivalence. (Madhavakara, 2012)

1. Introduction

Rheumatoid arthritis is among the most consequential chronic inflammatory arthritides because it combines persistent pain and stiffness with the potential for irreversible joint

destruction, work disability, systemic complications, and premature mortality. The disease commonly involves small joints symmetrically but its impact extends beyond the musculoskeletal system to cardiovascular, pulmonary, hematologic, neurologic, ocular,

and psychological domains. The modern therapeutic objective is therefore not simply analgesia; it is suppression of inflammatory disease activity to remission or low disease activity before cumulative damage occurs. (Radu & Bungau, 2021)

Epidemiological estimates vary according to geography, ascertainment method, age structure, and diagnostic criteria. A large systematic review estimated a pooled global prevalence of about 0.46%, whereas the Global Burden of Disease 2021 analysis estimated 17.6 million prevalent cases in 2020 and an age-standardized prevalence of 208.8 per 100,000. These estimates are lower than the older generalized statement that RA affects 0.8% of the world population, illustrating why current epidemiology should be presented with source and method rather than as a single universal percentage. (Almutairi et al., 2021)

The supplied Ayurvedic source material frames RA-like inflammatory joint disease through the concept of Amavata, first systematically described in Madhava Nidana. It attributes disease development to Mandagni, formation of Ama, aggravation of Vata, movement of the Ama-Vata complex through bodily channels, and localization in Sandhi, producing pain, swelling, stiffness, heaviness and systemic symptoms. This conceptual framework provides a traditional rationale for

therapeutic measures aimed at Ama-pachana, Agni support, reduction of obstruction, Vata management, and restoration of function. (Madhavakara, 2012)

The keyword Sandhivata is included because it is frequently encountered in Ayurvedic discussions of joint disease, but it should be differentiated from Amavata. Sandhivata is more commonly correlated with degenerative osteoarthritis, whereas Amavata is more often compared with inflammatory rheumatoid arthritis because of the presence of systemic features, inflammatory swelling, stiffness, and a pathogenesis centered on Ama with Vata. This distinction is important for scholarly accuracy and avoids conflating degenerative and autoimmune disease models. (Sharma, 2014)

2. Aim and Objectives

The aim of this article is to provide a standard, evidence-based and academically balanced review of rheumatoid arthritis as an autoimmune disorder, while critically examining the Ayurvedic concept of Amavata and the scientific evidence relevant to Ayurvedic management, immunomodulation and Rasayana-oriented supportive care. The objectives are to summarize modern RA epidemiology and pathogenesis; describe diagnostic and therapeutic standards; organize classical Amavata concepts from the supplied

material; compare overlapping clinical domains without asserting biological equivalence; assess evidence for selected Ayurvedic interventions; and identify methodological priorities for future integrative research. (Smolen et al., 2023)

3. Review Methodology

This article was prepared as an integrative narrative review rather than a new clinical experiment. The user-supplied literature document on Amavata was used as the primary traditional-source framework, and its statements were cross-checked against contemporary peer-reviewed literature and authoritative rheumatology guidance. Priority was given to systematic reviews, international classification criteria, professional-society treatment guidelines, Global Burden of Disease analyses, randomized or controlled clinical studies, and government-supported Ayurveda research sources. The literature was synthesized thematically because the interventions, populations and outcomes in Ayurvedic RA studies are too heterogeneous for a new quantitative meta-analysis within this article. (Chawla et al., 2026)

A deliberate distinction was maintained between classical Ayurvedic explanatory constructs and biomedical molecular mechanisms. Terms such as Ama, Agni, Dosha and Srotas are therefore described in their traditional clinical context, while cytokines,

autoantibodies, synovial fibroblasts and osteoclasts are used for modern RA biology. Conceptual parallels are discussed only at the level of clinical patterns or research hypotheses, because direct equivalence between these explanatory systems has not been scientifically established. (Patwardhan et al., 2011)


4. Epidemiology and Global Burden of Rheumatoid Arthritis

The contemporary global burden of RA is substantial and rising in absolute terms. In the GBD 2021 analysis, approximately 17.6 million people were living with RA in 2020 and the age-standardized prevalence rate had increased by about 14% from 1990. Females had an age-standardized prevalence approximately 2.45 times that of males, and projections suggested that about 31.7 million people could be living with RA by 2050 if demographic and epidemiological trends continue. (Black et al., 2023)

Disease burden is not fully captured by prevalence because RA is a long-duration condition associated with disability, treatment costs, work loss and comorbidity. The GBD analysis estimated approximately 3.06 million disability-adjusted life years in 2020, with years lived with disability accounting for the majority of this burden. Global mortality rates have declined over recent decades, likely

reflecting earlier recognition and more effective treatment, but prevalence and disability remain

major public-health challenges. (Black et al., 2023)



Source: Global Burden of Disease 2021 analysis reported by Black et al. (2023)

Figure 1. Global RA case burden in 2020 and projected burden in 2050. Data source: Black et al. (2023).

5. Etiology and Risk Factors

RA is a multifactorial disease rather than a disorder with a single cause. Genetic susceptibility is strongly influenced by variants within the HLA region, particularly HLA-DRB1 alleles carrying the shared epitope, while many non-HLA loci contribute smaller effects. Genetic risk interacts with environmental exposures and mucosal immune events, which helps explain why inherited susceptibility alone does not determine disease occurrence. (McInnes & Schett, 2011)

Cigarette smoking is one of the best-established modifiable environmental risk factors, especially for seropositive RA

characterized by anti-citrullinated protein antibodies. Other investigated influences include silica and occupational inhalants, periodontal inflammation, obesity, altered microbiota, reproductive and hormonal factors, and respiratory or mucosal exposures. The strength of evidence varies across these factors, so they should not be presented as equally causal. (Klingemann et al., 2025)

The traditional Amavata framework emphasizes etiological factors such as Viruddha Ahara, incompatible activities, Mandagni, inactivity and strenuous exercise after heavy or unctuous meals. These factors are interpreted within Ayurveda as promoting impaired digestion or metabolism, Ama

formation and Vata disturbance. Although these classical risk concepts cannot be translated directly into molecular causation, they provide a structured traditional history-taking framework focused on diet, activity, digestion and systemic symptoms. (Madhavakara, 2012)

6. Immunopathogenesis of Rheumatoid Arthritis


Modern RA pathogenesis begins before clinically apparent synovitis. In genetically susceptible individuals, environmental or mucosal triggers can promote post-translational protein modifications such as citrullination and facilitate a loss of immune tolerance. Autoantibodies including rheumatoid factor and ACPA may appear years before arthritis, indicating that a preclinical autoimmune phase can precede symptomatic joint inflammation. (McInnes & Schett, 2011)

Once inflammatory arthritis is established, synovial tissue becomes infiltrated by

macrophages, T cells, B cells, plasma cells and other immune cells. Fibroblast-like synoviocytes acquire an activated phenotype and participate actively in inflammation and tissue invasion. TNF, IL-6, IL-1 and related pathways sustain leukocyte recruitment, vascular activation and inflammatory signaling, while RANKL-mediated osteoclast differentiation contributes to bone erosion. (Firestein & McInnes, 2017)

B cells contribute through antigen presentation, cytokine production and autoantibody generation, while T-cell subsets influence both immune amplification and regulation. Th17-related signaling and disturbed regulatory mechanisms may contribute to persistent inflammation in selected patients. These overlapping networks explain why RA can respond to therapeutics that target different pathways, including TNF, IL-6 receptors, B cells, T-cell costimulation and intracellular Janus kinase signaling. (Smolen et al., 2023)

Conceptual immunopathogenesis of rheumatoid arthritis



Original schematic synthesized from contemporary RA immunopathogenesis literature.

Figure 2. Original schematic of major immunopathogenic stages in rheumatoid arthritis.

7. Clinical Manifestations

Typical articular RA presents with pain, swelling, tenderness and prolonged stiffness affecting multiple joints, often with a symmetrical distribution involving metacarpophalangeal, proximal interphalangeal and wrist joints. Persistent synovitis can progressively reduce grip strength, dexterity and mobility, and chronic uncontrolled disease can lead to deformity and erosive structural damage. Constitutional symptoms such as fatigue and reduced wellbeing may accompany active inflammation. (Wasserman, 2011)

RA is a systemic inflammatory condition and can produce extra-articular manifestations including rheumatoid nodules, interstitial lung disease, pleural disease, ocular inflammation, anemia, neuropathy and vasculitic complications. Cardiovascular risk is elevated through the combined influence of chronic

inflammation and conventional risk factors, which is why disease control and comorbidity management are both important components of long-term care. (Klingemann et al., 2025)

The supplied Amavata description lists Angamarda, Aruchi, Trushna, Alasya, Gaurava, Jwara, Apaka and Shunata Anganam among general features, with joint pain, swelling and stiffness becoming prominent when the disease localizes in Sandhi. Dosha-dominant clinical descriptions include severe pain with Vata predominance, burning or redness with Pitta involvement, and heaviness or itching with Kapha involvement. These patterns represent traditional clinical stratification rather than modern immunological phenotypes. (Madhavakara, 2012)

8. Diagnosis and Disease Activity Assessment

The 2010 ACR/EULAR classification criteria are designed to identify patients with

inflammatory synovitis who have a high probability of persistent or erosive RA. After confirming at least one clinically swollen joint not better explained by another disorder, points are assigned for the number and type of

involved joints, RF or ACPA serology, CRP or ESR status, and symptom duration. A total score of 6 or more out of 10 supports classification as definite RA. (Aletaha et al., 2010)

Domain	Finding	Score
Joint involvement	1 large joint	0
Joint involvement	2–10 large joints	1
Joint involvement	1–3 small joints	2
Joint involvement	4–10 small joints	3
Joint involvement	>10 joints, with at least 1 small joint	5
Serology	Negative RF and negative ACPA	0
Serology	Low-positive RF or low-positive ACPA	2
Serology	High-positive RF or high-positive ACPA	3
Acute-phase reactants	Normal CRP and ESR	0
Acute-phase reactants	Abnormal CRP or ESR	1
Symptom duration	<6 weeks	0
Symptom duration	≥6 weeks	1

Table 1. Simplified 2010 ACR/EULAR classification scoring for rheumatoid arthritis.

Classification criteria support research standardization but do not replace expert clinical diagnosis. Seronegative RA is possible, and imaging by radiography, ultrasonography or MRI may reveal synovitis or erosive change when clinical uncertainty remains. Disease activity is commonly monitored using composite measures such as DAS28, CDAI or SDAI, with patient-reported function and quality of life providing complementary information. (Fraenkel et al., 2021)

9. Contemporary Management of Rheumatoid Arthritis

The central principle of modern RA care is early initiation of a DMARD and adjustment of treatment according to a predefined target, usually remission or low disease activity. EULAR recommends starting DMARD therapy as soon as RA is diagnosed and emphasizes shared decision-making, regular disease-activity assessment, safety monitoring and consideration of comorbidities and structural progression. (Smolen et al., 2023)

Methotrexate remains the anchor conventional synthetic DMARD for many patients with moderate-to-high disease activity. The 2021 ACR guideline strongly recommends methotrexate monotherapy over hydroxychloroquine or sulfasalazine for DMARD-naïve patients with moderate-to-high activity and also favors methotrexate over starting a biologic or targeted synthetic DMARD as monotherapy in this setting. Treatment is individualized when contraindications, low disease activity, pregnancy-related considerations, organ disease or prior intolerance are present. (Fraenkel et al., 2021)

Biologic DMARDs and targeted synthetic DMARDs have transformed outcomes for patients who do not reach target with optimized conventional treatment. Available mechanisms include inhibition of TNF, IL-6 signaling, B-cell depletion, T-cell costimulation modulation and Janus kinase inhibition. These therapies require careful assessment of infection risk, vaccination status and drug-specific safety concerns, and they should be prescribed and monitored within specialist rheumatology care. (Smolen et al., 2023)

NSAIDs and glucocorticoids may reduce pain and inflammation but do not replace disease-modifying therapy. Contemporary guidance seeks to minimize glucocorticoid

exposure because cumulative toxicity can include infection, osteoporosis, diabetes, hypertension and other harms. This corrects the misconception that modern RA care only provides temporary symptomatic relief; current DMARD strategies can substantially suppress disease activity and prevent structural damage when used appropriately. (Fraenkel et al., 2021)


10. Ayurvedic Concept of Amavata

Amavata is classically conceptualized as a disorder in which impaired Agni produces Ama and aggravated Vata mobilizes this pathological material through the body. The combined Ama-Vata complex is described as obstructing channels and localizing in joints, where it produces pain, swelling, stiffness and restricted movement. This framework places digestive-metabolic disturbance and systemic circulation before overt joint disease and therefore guides treatment toward both systemic correction and local symptom relief. (Madhavakara, 2012)

The supplied source identifies Samprapti Ghataka that include Vata-predominant Tridosha involvement; Rasadi Dhatu with Asthi-related structures as affected tissues; Jatharagni and Rasadhatvagni dysfunction; Rasavaha and Asthivaha Srotas; Amashaya as Udbhava Sthana; Asthisandhi as Adhishtana; and Madhyama Rogamarga. These elements provide the classical structural vocabulary used

to analyze disease stage and select therapy. (Joshi, 2010)

Ayurvedic conceptual sequence (Samprapti) of Amavata



Conceptual diagram based on Madhava Nidana and the source material supplied by the user.

Figure 3. Original diagram summarizing the classical Samprapti sequence of Amavata.

11. Comparative Clinical Framework: RA and Amavata

RA and Amavata overlap most clearly at the level of inflammatory joint symptoms and systemic burden, but their diagnostic logics differ. RA is classified using observable synovitis, serology, inflammatory markers, symptom duration and imaging-supported

clinical judgment, whereas Amavata uses Ayurvedic assessment of Dosha, Ama, Agni, Srotas, stage and symptom patterns. A rigorous integrative model should retain both frameworks rather than forcing Ayurvedic terms to serve as direct substitutes for immunological markers. (Patwardhan et al., 2011)

Clinical domain	Rheumatoid arthritis perspective	Amavata perspective	Interpretive caution
Joint pain and swelling	Immune-mediated synovitis	Sandhishoola and Sandhishotha	Symptom overlap does not prove identical pathogenesis
Morning stiffness / restricted movement	Inflammatory stiffness and synovial thickening	Stambha and impaired movement	Comparable clinical phenomenon, different explanatory model
Systemic fatigue / heaviness	Cytokine-driven systemic disease, anemia, sleep and pain effects	Alasya, Gaurava, Angamarda	Useful symptom correlation only

Inflammatory markers	CRP, ESR; RF/ACPA for serology	No direct classical equivalent	Do not assign Ama to a laboratory biomarker without validation
Disease staging	Activity scores, erosions, functional status	Sama/Nirama state, Dosha, Agni and Srotas	Potentially complementary clinical stratification
Therapeutic target	Remission/low disease activity and damage prevention	Ama reduction, Agni support, Vata shamana, functional recovery	Biomedical disease control must not be delayed

Table 2. Comparative framework for discussing RA and Amavata without claiming direct biological equivalence.

12. Classical Ayurvedic Management

Principles

12.1 Langhana and Deepana-Pachana

Langhana is used in the supplied source as an early strategy for reducing the burden of Ama, with Upavasa or light dietary restriction and Pachana-oriented measures chosen according to patient strength and disease stage. Deepana refers to measures intended to support Agni, while Pachana is directed toward processing Ama. Because excessive fasting can worsen weakness or Vata-related symptoms, classical individualized assessment is essential and prolonged unsupervised fasting should not be extrapolated from textual principles. (Bhavamishra, 2016)

Tikta and Katu dominant substances are traditionally selected because they are described as light, drying, channel-clearing and supportive of Deepana-Pachana. From a modern research perspective, these traditional properties can generate hypotheses about

effects on appetite, gastrointestinal physiology, inflammatory signaling or metabolism, but such links require direct pharmacological and clinical validation rather than assumption. (Tripathi, 2013)

12.2 Swedana

Swedana is used in Amavata to address stiffness, pain and heaviness, particularly when selected in a dry or Ruksha form during Ama-dominant stages. Valuka Pottali Sweda and Churna Pottali Sweda are commonly described examples. The practical intent is to improve comfort and mobility without applying excessive unctuousness during the Sama stage, although safety considerations such as neuropathy, impaired thermal sensation, acute intense inflammation and skin disease must be considered clinically. (Mishra, 2016)

12.3 Virechana and Snehapana

Virechana is a controlled purgative procedure used after appropriate preparation and is traditionally considered more suitable

when the patient is in a Nirama state. Eranda Taila is frequently cited in Amavata because of its traditional Vata-anulomana and purgative use. Such procedures should be performed only under qualified Ayurvedic supervision because dehydration, electrolyte disturbance, drug interactions and comorbid disease can materially alter safety. (Mishra, 2016)

Snehapana requires stage-specific judgment because indiscriminate use of heavy or unctuous therapy is traditionally avoided in active Sama conditions. In Nirama states, appropriately processed Sneha may be used to counter excessive dryness and Vata aggravation after Langhana, Pachana or Swedana. This stage-sensitive approach is one reason standardized integrative trials should document Ayurvedic phenotype and treatment rationale rather than evaluating only a fixed herbal product. (Tripathi, 2013)

12.4 Basti

Basti has an important position in classical Vata management and the supplied material cites Saindhavadi Taila for Anuvasana and

Kshara or Vaitarana Basti for selected Amavata states. In modern clinical research, Basti-based protocols should be evaluated with explicit formulation standards, procedural details, contraindications, microbiological quality, adverse-event surveillance and validated RA outcome measures before broad claims of efficacy can be made. (Chawla et al., 2026)

13. Ayurvedic Formulations and Medicinal Plants Relevant to RA

Classical and contemporary Ayurvedic practice uses formulations such as Simhanada Guggulu, Rasnasaptaka Kwatha, Maharasnadi Kwatha, Yogaraja Guggulu, Panchasama Churna and Eranda-based preparations according to stage and constitution. The scientific interpretation of such polyherbal therapies is challenging because chemical composition varies with plant identity, geography, extraction, manufacturing, dose and co-administered procedures. Reproducible clinical evidence therefore depends on botanical authentication, marker-based standardization and batch-level quality control. (Chawla et al., 2026)

Ayurvedic drug / formulation	Traditional relevance	Selected modern research interest	Evidence limitation
Guduchi (<i>Tinospora cordifolia</i>)	Deepana, Rasayana, inflammatory conditions	Immunomodulatory and anti-inflammatory activity; used in RA polyherbal trials	Limited high-quality RA monotherapy trials; safety and product identity matter
Ashwagandha (<i>Withania somnifera</i>)	Rasayana, Balya, Vata-related disorders	Withanolides studied for anti-inflammatory	RA-specific clinical evidence remains

		and immunomodulatory effects	limited
Shunthi (Zingiber officinale)	Deepana-Pachana, Vata-Kapha disorders	Gingerols/shogaols influence inflammatory pathways	Most stronger clinical evidence is in pain/OA rather than RA
Shallaki (Boswellia serrata)	Shotha and joint disorders	Boswellic acids investigated for anti-inflammatory effects	RA trials are small and older; evidence encouraging but not conclusive
Haridra/Curcuma longa	Inflammatory conditions, wound and metabolic uses	Curcuminoids studied for NF-kB and inflammatory signaling	Bioavailability and formulation heterogeneity complicate interpretation
Simhanada Guggulu	Classical Amavata formulation	Clinical use and observational research in Amavata/RA	Need blinded, controlled, quality-assured trials

Table 3. Representative Ayurvedic plants/formulations relevant to inflammatory joint research.

14. Clinical Evidence for Ayurvedic Interventions in Rheumatoid Arthritis

One notable randomized investigator-blind multicenter study compared a standardized Ayurvedic polyherbal formulation, a *Semecarpus anacardium* preparation and hydroxychloroquine over 24 weeks in 121 patients with active RA. The standardized polyherbal arm contained extracts of *Zingiber officinale*, *Tinospora cordifolia*, *Withania somnifera* and *Tribulus terrestris*. The study suggested broadly comparable clinical efficacy between the polyherbal formulation and hydroxychloroquine on several measures, with mostly mild adverse events, but its exploratory design and limited power mean it should be

interpreted as supportive rather than definitive evidence. (Chopra et al., 2012)

A separate pilot study tested individualized classical Ayurvedic treatment, methotrexate, and their combination using a double-blind, double-dummy randomized design in seropositive RA. The study demonstrated the feasibility of rigorous blinding for a whole-system Ayurvedic intervention and reported broadly similar efficacy signals across groups within the limitations of a small pilot sample. The value of this study lies as much in its methodology as in its clinical estimates, because it showed that individualized Ayurveda can be investigated using contemporary controlled-trial methods. (Furst et al., 2011)

The most recent systematic review identified 21 comparative clinical studies of oral Ayurvedic interventions for RA/Amavata published between 2010 and 2024, including 15 randomized and six non-randomized studies. Many studies reported improvement in pain, tenderness, stiffness, swelling, ESR or other outcomes, but the reviewers judged the overall risk of bias to be high because randomization, allocation concealment, blinding, attrition handling, standardized outcomes and adverse-event reporting were frequently inadequate. (Chawla et al., 2026)

Safety reporting was a particularly important weakness: only a small minority of studies reported formal CBC, liver and kidney testing or structured adverse-event assessment. This is clinically significant because Ayurvedic products can vary in composition and may interact with DMARDs or other medicines, while some herbo-mineral preparations require additional quality assurance for elemental contaminants. The absence of reported toxicity should therefore never be interpreted as proof of safety when surveillance itself was incomplete. (Chawla et al., 2026)




Figure 4. Trial-design and safety-reporting profile in the 2026 systematic review of Ayurvedic RA interventions.

15. Immunomodulation and Rasayana: Scientific Interpretation

Immunomodulation is a useful research term when supported by experimentally

demonstrated effects on immune cells, cytokines, transcription factors or antibody responses. Several Ayurvedic botanicals contain compounds that influence inflammatory signaling in vitro or in animal

models, but an immunomodulatory laboratory effect is not equivalent to proven disease modification in human RA. Clinical claims should therefore be anchored to outcomes such as DAS28, ACR response, CRP/ESR, function, imaging progression and treatment safety. (Radu & Bungau, 2021)

Rasayana is a broader Ayurvedic therapeutic concept related to resilience, nourishment, functional maintenance and healthy aging. In RA research, Rasayana-oriented interventions could be investigated for fatigue, physical function, sleep, quality of life, sarcopenia risk, treatment tolerance or recovery after inflammatory control, rather than being framed as a substitute for suppression of active synovitis. Such positioning creates clinically testable questions while respecting the traditional concept. (Patwardhan et al., 2011)

16. Integrative Therapeutic Strategy

An evidence-responsible integrative strategy begins with confirmation of RA by a

qualified rheumatology team, assessment of disease activity and prognostic factors, and timely initiation of DMARD therapy when indicated. Ayurveda may then be considered as an adjunct for individualized symptom management, lifestyle support and potentially complementary anti-inflammatory care, provided the treating clinicians are aware of all medicines and the patient is monitored for disease activity, organ toxicity and interactions. (Smolen et al., 2023)

This model avoids two unsafe extremes: first, delaying effective DMARD treatment in active RA while irreversible erosions accumulate; and second, dismissing all traditional interventions despite emerging but incomplete evidence. A rational pathway is to combine rigorous rheumatology monitoring with standardized Ayurvedic practice, document outcomes prospectively and discontinue or modify any adjunct that causes toxicity, interactions or worsening disease control. (Fraenkel et al., 2021)

Clinical phase	Biomedical priority	Potential supervised Ayurvedic contribution	Monitoring
Suspected early inflammatory arthritis	Urgent rheumatology assessment; RF/ACPA, CRP/ESR; classify and exclude mimics	Diet/lifestyle history and non-delaying supportive care	Joint examination, labs, referral time
Confirmed active RA	Start/optimize DMARD; treat-to-target	Stage-appropriate adjunctive interventions after interaction review	DAS28/CDAI, CRP/ESR, CBC/LFT/KFT
Persistent symptoms	Assess damage,	Supervised symptom-	Pain/function/QoL and

despite controlled inflammation	fibromyalgia, sleep, mood, deconditioning	oriented therapies, rehabilitation, Rasayana research approaches	adverse events
Remission or low disease activity	Maintain safe disease control; cautious tapering only per guideline	Lifestyle, mobility, nutrition, wellbeing support	Flare surveillance and medication safety

Table 4. Proposed evidence-responsible framework for integrative RA care.

17. Safety, Quality Control and Herb–Drug Interaction Considerations

Quality control is central to the scientific evaluation of Ayurvedic medicines. Botanical identity, plant part, extraction method, marker compounds, microbial limits, pesticides, adulterants, heavy metals, storage and batch reproducibility can all influence efficacy and safety. Clinical trials should therefore report manufacturing standards and certificate-of-analysis data wherever possible, especially for multi-ingredient products. (Chawla et al., 2026)

Potential herb–drug interactions deserve structured surveillance because patients with RA may simultaneously use methotrexate, leflunomide, hydroxychloroquine, glucocorticoids, NSAIDs, biologics or JAK inhibitors. Interventions with hepatic, renal, immunologic, antiplatelet or gastrointestinal effects may alter the safety profile of conventional treatment even when the herb itself is traditionally regarded as safe. Medication reconciliation and laboratory monitoring should therefore be part of

integrative care and future trials. (Fraenkel et al., 2021)

18. Research Gaps and Future Directions

Future Ayurvedic RA trials need adequately powered multicenter designs, transparent randomization, allocation concealment, assessor blinding where full participant blinding is impractical, prespecified primary outcomes and intention-to-treat analysis. Standard RA endpoints should include DAS28-CRP or equivalent disease activity measures, ACR20/50/70 response, validated disability indices, quality-of-life measures, rescue medication use and complete adverse-event reporting. (Chawla et al., 2026)

Ayurveda-specific variables should also be recorded prospectively rather than discarded. These may include Sama/Nirama status, Agni assessment, Dosha predominance, relevant dietary patterns and the rationale for individualized treatment selection. This would allow investigators to test whether classical stratification predicts response while still

preserving comparability through standardized biomedical outcomes. (Patwardhan et al., 2011)

Mechanistic studies should move beyond generic claims of antioxidant or anti-inflammatory activity and connect standardized interventions to specific biological pathways. Useful translational endpoints could include cytokine panels, immune-cell phenotyping, ACPA/RF dynamics, metabolomics, microbiome signatures or imaging inflammation, but only when linked to clinical outcomes and predefined hypotheses. Such studies may identify responder phenotypes and distinguish symptomatic improvement from true disease modification. (Firestein & McInnes, 2017)

Longer follow-up is particularly important because RA is chronic and fluctuating. A short reduction in pain does not establish prevention of erosions, sustained remission or steroid-sparing benefit. Trials should therefore incorporate relapse rates, durability of response, cumulative glucocorticoid exposure, radiographic or imaging progression where feasible, and pharmacovigilance extending beyond the active treatment phase. (Smolen et al., 2023)

19. Discussion

The strongest conclusion from the combined evidence is that RA requires early disease-modifying treatment, while Ayurvedic

approaches remain a promising but incompletely validated adjunctive field. The traditional Amavata construct organizes symptoms, digestive-metabolic context and stage-sensitive therapy in a clinically coherent manner, but direct equivalence with autoantibody formation, cytokine biology or synovial histopathology has not been established. An academically defensible integrative paper should therefore preserve conceptual distinctions while identifying areas where outcomes can be measured jointly. (Aletaha et al., 2010)

The available Ayurvedic clinical literature is encouraging in that multiple interventions have reported improvement in pain, swelling, stiffness, function and inflammatory markers, and some controlled studies have used active comparators such as hydroxychloroquine or methotrexate. Yet heterogeneity and high risk of bias substantially reduce certainty. The correct scientific response is neither rejection nor overstatement, but better trials with standardized products, transparent methods, independent replication and modern safety reporting. (Chawla et al., 2026)

This evidence balance also supports careful wording around the concept of “cure.” Modern RA treatment does not guarantee permanent cure, but it can induce sustained remission, markedly reduce inflammation, prevent or slow

structural damage and improve survival and function. Ayurveda may contribute useful adjunctive strategies, but current evidence does not justify replacing effective DMARDs in patients with active disease. (Smolen et al., 2023)

20. Conclusion

Rheumatoid arthritis is a systemic autoimmune inflammatory disease with a growing global burden and a well-characterized risk of joint destruction and multisystem morbidity when inadequately controlled. Advances in classification, treat-to-target strategies and DMARDs have substantially improved prognosis, making early diagnosis and timely disease modification the standard of care. (Black et al., 2023)

Amavata provides a detailed Ayurvedic framework for an inflammatory joint syndrome characterized by Ama, impaired Agni, Vata aggravation, channel obstruction and joint localization. Its management emphasizes Langhana, Deepana-Pachana, Swedana, stage-appropriate Shodhana, Basti and selected herbal formulations, with Rasayana-oriented support potentially relevant to function and wellbeing. These concepts are valuable for integrative research when described on their own terms and evaluated with standardized clinical endpoints. (Madhavakara, 2012)

The current clinical evidence for Ayurvedic RA interventions shows therapeutic potential but remains insufficient for strong claims of disease modification because of methodological weaknesses and inconsistent safety reporting. The most productive future direction is rigorous integrative research that combines quality-controlled Ayurvedic interventions with rheumatology-grade diagnosis, disease activity measurement, pharmacovigilance and transparent reporting. (Chawla et al., 2026)

References

1. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis.* 2010;69:1580-1588. doi:10.1136/ard.2010.138461.
2. Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. *Rheumatol Int.* 2021;41:863-877. doi:10.1007/s00296-020-04731-0.
3. Black RJ, Cross M, Haile LM, et al. Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global

- Burden of Disease Study 2021. *Lancet Rheumatol.* 2023;5:e594-e610.
4. Chawla D, Borkar P, Singh R, Manathottathil A. Efficacy and Safety of Ayurvedic Interventions in the Management of Rheumatoid Arthritis: A Systematic Review. *J Clin Diagn Res.* 2026;20(6):JC12-JC21. doi:10.7860/JCDR/2026/80367.23668.
 5. Chopra A, Saluja M, Tillu G, et al. Comparable efficacy of standardized Ayurveda formulation and hydroxychloroquine sulfate in the treatment of rheumatoid arthritis: a randomized investigator-blind controlled study. *Clin Rheumatol.* 2012;31:259-269. doi:10.1007/s10067-011-1809-z.
 6. Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. *Immunity.* 2017;46(2):183-196. doi:10.1016/j.immuni.2017.02.006.
 7. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res.* 2021;73:924-939. doi:10.1002/acr.24596.
 8. Furst DE, Venkatraman MM, McGann M, et al. Double-blind, randomized, controlled pilot study comparing classic Ayurvedic medicine, methotrexate, and their combination in rheumatoid arthritis. *J Clin Rheumatol.* 2011;17(4):185-192.
 9. Klingemann L, Mikuls TR, England BR. Epidemiology and outcomes of rheumatoid arthritis. *Curr Opin Rheumatol.* 2025;38(2):69-75.
 10. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. *N Engl J Med.* 2011;365:2205-2219. doi:10.1056/NEJMr1004965.
 11. Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. *Cells.* 2021;10(11):2857. doi:10.3390/cells10112857.
 12. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. *Ann Rheum Dis.* 2023;82:3-18. doi:10.1136/ard-2022-223356.
 13. Wasserman AM. Diagnosis and management of rheumatoid arthritis. *Am Fam Physician.* 2011;84(11):1245-1252.
 14. Ernst E. Frankincense: systematic review. *BMJ.* 2008;337:a2813. doi:10.1136/bmj.a2813.
 15. Patwardhan B, Vaidya ADB, Chorghade M, Joshi SP. Ayurveda and natural products drug discovery. *Curr Sci.* 2004;86:789-799.

16. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. *Evid Based Complement Alternat Med.* 2005;2:465-473.
17. Tripathi B, editor. *Charaka Samhita of Agnivesha with Charaka Chandrika commentary.* Varanasi: Chaukhambha Surbharati Prakashan; 2013.
18. Shastri AD, editor. *Sushruta Samhita with Ayurveda Tattva Sandipika commentary.* Varanasi: Chaukhambha Sanskrit Sansthan; 2010.
19. Mishra BS, editor. *Bhavaprakasha of Bhavamishra with Vidyotini Hindi Commentary.* Vol II. Varanasi: Chaukhambha Sanskrit Bhawan; 2016.
20. Madhavakara. *Madhava Nidana with Madhukosha commentary of Vijayarakshita and Srikanthadatta.* Varanasi: Chaukhambha Sanskrit series; cited edition 2012.
21. Joshi YG. *Kayachikitsa: Amavata Adhyaya.* Pune: Ayurvedic academic text; cited source edition.
22. Sharma PV. *Dravyaguna Vijnana.* Varanasi: Chaukhambha Bharati Academy; cited standard edition.
23. Saha S, Ghosh S. *Tinospora cordifolia: validation of Ayurvedic pharmacology through experimental and clinical studies.* *Int J Ayurveda Res.* 2010;1(2):112-121.
24. Cameron M, Gagnier JJ, Chrubasik S. Herbal therapy for treating rheumatoid arthritis. *Cochrane Database Syst Rev.* 2011;CD002948.
25. Bullock J, Rizvi SAA, Saleh AM, et al. Rheumatoid arthritis: a brief overview of the treatment. *Med Princ Pract.* 2018;27(6):501-507. doi:10.1159/000493390.
26. Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis.* 2010;69:631-637.
27. Studenic P, Aletaha D, de Wit M, et al. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. *Ann Rheum Dis.* 2023;82:74-80.
28. Kumar S, Dobos GJ, Rampp T. The significance of Ayurvedic medicinal plants. *J Evid Based Complementary Altern Med.* 2017;22(3):494-501.
29. Central Council for Research in Ayurvedic Sciences (CCRAS). *Clinical Research Programme and ongoing rheumatoid arthritis studies.* Ministry of Ayush, Government of India. Accessed 2026.

30. National AYUSH Morbidity and Standardized Terminologies Electronic Portal (NAMASTE). Ministry of Ayush, Government of India. Disease terminology resource for Ayurveda.